ArticleAnimal genetics2026
Stage-Dependent Transcriptional Reprogramming of B-Cell Receptor Signaling and Antigen Presentation During Bovine Leukemia Virus-Driven Lymphomagenesis.
Article in Animal genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine leukemia virus (BLV), an oncogenic deltaretrovirus, establishes lifelong infection in cattle and induces enzootic bovine leukosis in a subset of animals following prolonged latency. Despite extensive evidence of immune dysregulation, stage-specific transcriptional reprogramming of B cells, the primary viral reservoir remains incompletely understood. In this study, we performed a targeted RNA-sequencing analysis to characterize B-cell-associated transcriptional profiles across three clinical stages: uninfected controls (CT), asymptomatic BLV-infected cattle (AC), and persistent lymphocytosis (PL). Differential gene expression analysis revealed a dynamic, stage-dependent remodeling of B-cell immune functions. Asymptomatic infection was characterized by significant upregulation of key B-cell receptor (BCR) signaling components, including CD79B and SYK, alongside increased expression of major histocompatibility complex class II genes (BoLA-DRA, BoLA-DRB3) and immunoglobulin assembly gene JCHAIN, indicating enhanced antigen responsiveness and partial activation of antibody-related pathways. However, transcriptional regulators of terminal plasma cell differentiation (PRDM1 and XBP1) remained unchanged, suggesting incomplete maturation. In contrast, progression to persistent lymphocytosis was associated with attenuation of canonical BCR signaling and reduced expression of antigen presentation and immunoglobulin assembly genes relative to the asymptomatic stage. Notably, germinal center-associated transcription factors (BCL6, AICDA, RGS13, MEF2B) remained largely unchanged across all comparisons, indicating that BLV-driven lymphomagenesis does not resemble a classical germinal center-derived process. Collectively, these findings support a biphasic model of BLV-induced B-cell modulation, characterized by early immune activation followed by functional reprogramming and immune attenuation during disease progression. This stage-dependent remodeling provides new mechanistic insights into BLV pathogenesis and B-cell transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.